论文部分内容阅读
日本要求更改Ｉｄａｒｕｂｉｃｉｎ的使用标签Ｉｄａｒｕｂｉｃｉｎ是法玛西亚·普强（Ｐ＆Ｕ）公司上市的一种抗癌药，主要用于治疗白血病，目前已在世界上约７０个国家销售。在日本，根据有关法律的要求，此药自１９９５年在该国上市后，一直进行“上市后监测”（ＰＭＳ...
Japan Request Changed Idarubicin’s Usage Label Idarubicin is an anti-cancer drug marketed by the French company Pharisea P & U for the treatment of leukemia and is currently sold in about 70 countries around the world. In Japan, following the listing of the drug in 1995 in the country, the drug has been “post-market surveillance” (PMS ...